© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
selective oral LTA4H metalloenzyme inhibitor
in multiple inflamm. Ph. II incl. colitis + NASH
1800 cmpd fragment screen + frag. merging
J. Med. Chem., Feb. 16, 2021
Novartis, Basel, CH
2. The Novartis LTA4H metalloenzyme inhibitor, LYS006, is a selective oral agent in multiple Ph. II studies to treat inflammatory diseases including ulcerative colitis and NASH. The starting points…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.